This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	AT rich interactive domain 1A (ARID1A); protein phosphatase 2, regulatory subunit A α (PPP2R1A)	<p>A study in human tumor samples suggests that mutations in <i>ARID1A</i> and <i>PPP2R1A</i> could contribute to ovarian clear cell carcinoma and might provide a diagnostic marker or help identify new therapeutic targets. Genetic sequencing of 42 tumor samples showed that 57% had mutations in <i>ARID1A</i> and 7% had mutations in <i>PPP2R1A</i>. Next steps include developing a test to detect <i>ARID1A</i> mutations and identifying genes whose expression is modified by these mutations.</p> <p>SciBX 3(36); doi:10.1038/scibx.2010.1090 Published online Sept. 16, 2010</p>	Patent and licensing status undisclosed	<p>Jones, S. <i>et al. Science</i>; published online Sept. 9, 2010; doi:10.1126/science.1196333 Contact: Nickolas Papadopoulos, Johns Hopkins Medical Institutes, Baltimore, Md. e-mail: npapado1@jhmi.edu Contact: Kenneth W. Kinzler, same affiliation as above e-mail: kinzlk@jhmi.edu Contact: Victor E. Velculescu, same affiliation as above e-mail: velculescu@jhmi.edu</p>